SERPINA1 gene editing therapy (Korro Bio/Genevant Sciences)

N/A

Report date: 2025/01/26 17:51:21
NME

Base Information

Drug NameSERPINA1 gene editing therapy (Korro Bio/Genevant Sciences)
Drug Alias NameRNA editing therapy (Korro Bio)RNA editing therapy (Korro Bio/Genevant Sciences)SERPINA1 gene editing therapy (Korro Bio)
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionAlpha-1-antiproteinase modulators
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKorro Bio OpCo Inc
China Registration ClassN/A

Develop Information

Active CompaniesKorro Bio OpCo IncGenevant Sciences
Inactive CompaniesN/A
Active Indicationsalpha 1-Antitrypsin Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A